CLAIMS

1. A liquid composition comprising botulinum neurotoxin (BoNT) for use in treating moderate to severe glabellar lines (GL) and/or lateral canthal lines (LCL) in a human subject,

wherein said liquid composition further comprises the following components to provide a liquid formulation of BoNT that is stable when stored:

a. a source of chloride ions selected from NaCL at concentration of 100-300 mM, and KCl at a concentration of 1-25 mM;

b. more than one source of phosphate ions selected from sodium phosphate, potassium phosphate, di-sodium hydrogen phosphate, dehydrate, and sodium dihydrogen phosphate dehydrate, at a concentration of 1-50 mM;

c. a non-ionic surfactant at a concentration of 0.01-5% (v/v); and

d. an amino acid stabilizer selected from alanine, valine, leucine, isoleucine, methionine, phenylalanine, tyrosine, and tryptophan, at a concentration of 0.1-3mg/ml.

2. The liquid composition for use according to claim 1, wherein the composition comprises more than one source of chloride ions.

3. The liquid composition for use of claim 1 or claim 2, wherein the amino acid is in the L isoform.

4. The liquid composition for use of any one of the preceding claims, wherein the amino acid is present at a concentration of about 0.75 to about 2.25 mg/mL.

5. The liquid composition for use of any one of the preceding claims, wherein the non-ionic surfactant is a polysorbate.

6. The liquid composition for use of any one of the preceding claims, wherein the botulinum neurotoxin is selected from the group consisting of botulinum neurotoxin types A, B, C, D, E, F and G; preferably

wherein the botulinum neurotoxin is botulinum neurotoxin type A.

7. The liquid composition for use of any one of the preceding claims, wherein the pH of the liquid composition is between 6.6 and 6.9.

8. The liquid composition for use of any one of the preceding claims, wherein the osmolality of the liquid composition is between 270 mosm/kg and 310 mosm/kg.

9. The liquid composition for use of any one of any one of the preceding claims, wherein between 1 and 100 units of botulinum toxin is administered to the subject, wherein 1 Unit is an amount of the botulinum neurotoxin corresponds to the calculated median lethal dose (LD50) in mice; optionally wherein:

a) between 10 and 75 units of botulinum toxin is administered to the subject.

b) between 25 and 75 units of botulinum toxin is administered to the subject; or

c) 10, 25, 30, 45, 50, 60, 75, or 90 units of botulinum toxin is administered to the subject.

10. The liquid composition for use of any one of the preceding claims, wherein the liquid composition is administered by subdermal, transdermal, intradermal or intramuscular injection; optionally

wherein the subject is injected multiple times in the glabellar region.

11. The liquid composition for use of claim 10, wherein adjacent injections are separated by about 0.5 to about 10 cm; or wherein adjacent injections are separated by about 1.5 to about 3 cm.

12. The liquid composition for use of any one of claims 10-11, wherein the injections are in the procerus muscle and the corrugator supercillii muscles on each side of the face, wherein the injections are first made in the procerus muscle followed by the corrugator supercillii muscles on each side of the face, moving outwards from the median.

13. The liquid composition for use of any one of claims 10-12, wherein all the injections are about 1 cm above the upper orbital rim and internal to the mid-pupillary lines; and/or

wherein all the injections are at least 1 cm above the central eyebrow or the bony supraorbital ridge; and/or

further comprising applying pressure on the upper orbital rim while injecting to minimize risks of regional effect of the botulinum neurotoxin; and/or

wherein the subject is further injected multiple times below the lateral canthus, in the external part of the orbicularis oculi, and/or 1-2 cm from the orbital rim.

14. The liquid composition for use of claim 10, wherein the subject is injected multiple times below the lateral canthus, in the external part of the orbicularis oculi, and/or 1-2 cm from the orbital rim.

15. The liquid composition for use of any one of the preceding claims, wherein said treatment is repeated at intervals from about 1 month to about 6 months to inhibit said recurrence; optionally

wherein said treatment is repeated at intervals from about 3 months to about 6 months to inhibit said recurrence; or

wherein said treatment is repeated at intervals of about 4 months to inhibit said recurrence.